Demographic and clinical correlates of substance use disorders in first episode psychosis

Schizophrenia Research

Volumn 194, Issue , 2018, Pages 4-12

  Brunette, Mary F ^a,b   Mueser, Kim T ^c   Babbin, Steven ^d   Meyer Kalos, Piper ^e   Rosenheck, Robert ^f   Correll, Christoph U ^g,h,i,j   Cather, Corrine ^s   Robinson, Delbert G ^g,h,i,j   Schooler, Nina R ^g,k   Penn, David L ^l,m   Addington, Jean ⁿ   Estroff, Sue E ^o   Gottlieb, Jennifer ^c   Glynn, Shirley M ^p   Marcy, Patricia ^q   Robinson, James ^r   Kane, John M ^g,h,i,j  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Bureau of Mental health services ohio Department of Rehabilitation and Correction   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ZUCKER HILLSIDE HOSPITAL   (United States)

^h FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

ⁱ DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^k Downstate Health Sciences University   (United States)

^l University of North Carolina at Chapel Hill   (United States)

^m AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q Vanguard Research Group   (United States)

^r NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Alcohol; Cannabis; Drug; First episode; Schizophrenia; Substance use disorder

Indexed keywords

ALCOHOL; CANNABIS;

ADULT; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CAUCASIAN; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; COOPERATION; DEMOGRAPHY; DEPRESSION; DRUG DEPENDENCE; DSM-IV; FEMALE; HOSTILITY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; PRIORITY JOURNAL; PSYCHOSIS; RACE; SEX DIFFERENCE; UNITED STATES; ACUTE DISEASE; COMORBIDITY; COMPLICATION; ODDS RATIO; PSYCHOLOGICAL INTERVIEW; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA; STATISTICAL MODEL; YOUNG ADULT;

ACUTE DISEASE; COMORBIDITY; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; LOGISTIC MODELS; MALE; ODDS RATIO; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 85022036514     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2017.06.039     Document Type: Article

References (99)

1. Addington, J., Early intervention strategies for co-morbid cannabis use and psychosis. Inaugural International Cannabis and Psychosis Conference, Melbourne, 1999.
2. Addington, J., Addington, D., Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr. Scand. 115:4 (2007), 304–309.
3. Addington, D., Addington, J., Maticka-Tyndale, E., Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 22 (1993), 39–44.
4. Addington, J., Heinssen, R.K., Robinson, D.G., Schooler, N.R., Marcy, P., Brunette, M.F., Correll, C.U., Estroff, S., Mueser, K.T., Penn, D., Robinson, J.A., Rosenheck, R.A., Azrin, S.T., Goldstein, A.B., Severe, J., Kane, J.M., Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatr Serv. 2015 (appips201400124).
5. Baeza, I., Graell, M., Moreno, D., Castro-Fornieles, J., Parellada, M., González-Pinto, A., Payá, B., Soutullo, C., de la Serna, E., Arango, C., Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr. Res. 113:2–3 (2009), 129–137.
6. Barnett, J.H., Werners, U., Secher, S.M., Hill, K.E., Brazil, R., Masson, K., Pernet, D.E., Kirkbride, J.B., Murray, G.K., Bullmore, E.T., Jones, P.B., Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 190 (2007), 515–520.
7. Barrowclough, C., Gregg, L., Lobban, F., Bucci, S., Emsley, R., The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophr. Bull. 41:2 (2015), 382–390.
8. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O'Carroll, C.M., Seal, M., Allen, P., Mehta, M.A., Stone, J.M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R.M., Zuardi, A.W., Crippa, J.A., Atakan, Z., McGuire, P.K., Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:3 (2010), 764–774.
9. Brunette, M.F., Noordsy, D.L., Green, A.I., Co-occurring substance use and other psychiatric disorders. Lieberman, J.A., Stroup, T.S., Perkins, D., (eds.) Textbook of Schizophrenia, 2nd Edition, 2016, American Psychiatric Press, Washington, D.C.
10. Bühler, B., Hambrecht, M., Löffler, W., An der Heiden, W., Häfner, H., Precipitation and determination of the onset and course of schizophrenia by substance abuse—a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 54 (2002), 243–251.
11. Cacciola, J.S., Alterman, A.I., Rutherford, M.J., McKay, J.R., Mulvaney, F.D., The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 61:3 (2001), 271–280.
12. Childs, H.E., McCarthy-Jones, S., Rowse, G., Turpin, G., The journey through cannabis use: a qualitative study of the experiences of young adults with psychosis. J. Nerv. Ment. Dis. 199:9 (2011), 703–708.
13. Colizzi, M., Bhattacharyya, S., Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr. Addict. Rep. 4:2 (2017), 62–74.
14. Compton, W.M., Thomas, Y.F., Stinson, F.S., Grant, B.F., Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 64:5 (2007), 566–576.
15. Compton, M.T., Kelley, M.E., Ramsay, C.E., Pringle, M., Goulding, S.M., Esterberg, M.L., Stewart, T., Walker, E.F., Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am. J. Psychiatry 166:11 (2009), 1251–1257.
16. Degenhardt, L., Hall, W., The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-being. Psychol. Med. 31:4 (2001), 659–668.
17. DeJong, W., Blanchette, J., Case closed: research evidence on the positive public health impact of the age 21 minimum legal drinking age in the United States. J. Stud. Alcohol Drug Suppl. 75:Suppl. 17 (2014), 108–115.
18. Dekker, N., Meijer, J., Koeter, M., van den Brink, W., van Beveren, N., Kahn, R.S., Linszen, D.H., van Os, J., Wiersma, D., Bruggeman, R., Cahn, W., de Haan, L., Krabbendam, L., Myin-Germeys, I., Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychol. Med. 42:9 (2012), 1903–1911.
19. Desmarais, S.L., Van Dorn, R.A., Sellers, B.G., Young, M.S., Swartz, M.S., Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia. Psychol. Addict. Behav. 27:3 (2013), 774–787.
20. Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S.A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., Dazzan, P., Mondelli, V., Paparelli, A., Kolliakou, A., Prata, D., Gaughran, F., David, A.S., Morgan, C., Stahl, D., Khondoker, M., MacCabe, J.H., Murray, R.M., Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 40:6 (2014), 1509–1517.
21. Dolder, C.R., Lacro, J.P., Warren, K.A., Golshan, S., Perkins, D.O., Jeste, D.V., Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J. Clin. Psychopharmacol. 24:4 (2004), 404–409.
22. Drake, R.E., Rosenberg, S.D., Mueser, K.T., Assessing substance use disorder in persons with severe mental illness. New Dir. Ment. Health Serv. 70 (1996), 3–17.
23. Estroff, S.E., Penn, D.L., Toporek, J.R., From stigma to discrimination: an analysis of community efforts to reduce the negative consequences of having a psychiatric disorder and label. Schizophr. Bull. 30:3 (2004), 493–509.
24. Evins, A.E., Green, A.I., Kane, J.M., Murray, R.M., The effect of marijuana use on the risk for schizophrenia. J. Clin. Psychiatry 73:11 (2012), 1463–1468.
25. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., Structured Clinical Interview for DSM-IV Axis-I Disorders - Patient Edition (SCID-I/P, Version 2.0). 1996, Biometrics Research Department, New York.
26. Ford, J.D., Gelernter, J., DeVoe, J.S., Zhang, W., Weiss, R.D., Brady, K., Farrer, L., Kranzler, H.R., Association of psychiatric and substance use disorder comorbidity with cocaine dependence severity and treatment utilization in cocaine-dependent individuals. Drug Alcohol Depend. 99:1–3 (2009), 193–203.
27. Foti, D.J., Kotov, R., Guey, L.T., Bromet, E.J., Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am. J. Psychiatry 167:8 (2010), 987–993.
28. Grant, B.F., Goldstein, R.B., Saha, T.D., Chou, S.P., Jung, J., Zhang, H., Pickering, R.P., Ruan, W.J., Smith, S.M., Huang, B., Hasin, D.S., Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry 72:8 (2015), 757–766.
29. Grech, A., Van Os, J., Jones, P.B., Lewis, S.W., Murray, R.M., Cannabis use and outcome of recent onset psychosis. Eur. Psychiatry 20:4 (2005), 349–353.
30. Green, A.I., Tohen, M., Hamer, R.M., Strakowski, S.M., Lieberman, J., Glick, I., Clark, W.S., Group, H.R., First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 66:2–3 (2004), 125–135.
31. Harrison, I., Joyce, E.M., Mutsatsa, S.H., Hutton, S.B., Huddy, V., Kapasi, M., Barnes, T.R., Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol. Med. 38:1 (2008), 79–88.
32. Hasin, D.S., Kerridge, B.T., Saha, T.D., Huang, B., Pickering, R., Smith, S.M., Jung, J., Zhang, H., Grant, B.F., Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions-III. Am. J. Psychiatry 173:6 (2016), 588–599.
33. Heinrichs, D.W., Hanlon, T.E., Carpenter, W.T.J., The quality of life scale: an instrument for rating the schizophrenia deficit syndrome. Schizophr. Bull. 10 (1984), 388–396.
34. Heinssen, R.K., Goldstein, A.B., Azrin, S.T., Evidence-Based Treatments for First Episode Psychosis: Components of Coordinated Specialty Care. 2014, National Institute of Mental Health.
35. Helle, S., Ringen, P.A., Melle, I., Larsen, T.K., Gjestad, R., Johnsen, E., Lagerberg, T.V., Andreassen, O.A., Kroken, R.A., Joa, I., Ten Velden Hegelstad, W., Løberg, E.M., Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119). Schizophr. Res. 170:1 (2016), 217–221.
36. Hides, L., Dawe, S., Kavanagh, D.J., Young, R.M., Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br. J. Psychiatry 189 (2006), 137–143.
37. Hinton, M., Edwards, J., Elkins, K., Harrigan, S.M., Donovan, K., Purcell, R., McGorry, P.D., Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Interv. Psychiatry 1 (2007), 259–266.
38. Huber, C.G., Hochstrasser, L., Meister, K., Schimmelmann, B.G., Lambert, M., Evidence for an agitated-aggressive syndrome in early-onset psychosis correlated with antisocial personality disorder, forensic history, and substance use disorder. Schizophr. Res. 175:1–3 (2016), 198–203.
39. Iseger, T.A., Bossong, M.G., A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr. Res. 162:1–3 (2015), 153–161.
40. Kamali, M., McTigue, O., Whitty, P., Gervin, M., Clarke, M., Browne, S., Larkin, C., O'Callaghan, E., Lifetime history of substance misuse in first-episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms. Early Interv. Psychiatry 3:3 (2009), 198–203.
41. Kane, J.M., Robinson, D.G., Schooler, N.R., Mueser, K.T., Penn, D.L., Rosenheck, R.A., Addington, J., Brunette, M.F., Correll, C.U., Estroff, S.E., Marcy, P., Robinson, J., Meyer-Kalos, P.S., Gottlieb, J.D., Glynn, S.M., Lynde, D.W., Pipes, R., Kurian, B.T., Miller, A.L., Azrin, S.T., Goldstein, A.B., Severe, J.B., Lin, H., Sint, K.J., John, M., Heinssen, R.K., Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am. J. Psychiatry, 2015 (appiajp201515050632).
42. Kavanagh, D.J., Waghorn, G., Jenner, L., Chant, D.C., Carr, V., Evans, M., Herrman, H., Jablensky, A., McGrath, J.J., Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiologic sample. Schizophr. Res. 66 (2004), 115–124.
43. Kay, S.R., Opler, L.A., Fiszbein, A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
44. Keefe, R.S., Goldberg, T.E., Harvey, P.D., Gold, J.M., Poe, M.P., Coughenour, L., The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 68:2–3 (2004), 283–297.
45. Kerridge, B.T., Saha, T.D., Chou, S.P., Zhang, H., Jung, J., Ruan, W.J., Smith, S.M., Huang, B., Hasin, D.S., Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: results from the national epidemiologic survey on alcohol and related conditions - III. Drug Alcohol Depend. 156 (2015), 47–56.
46. King, M., Dinos, S., Shaw, J., Watson, R., Stevens, S., Passetti, F., Weich, S., Serfaty, M., The stigma scale: development of a standardised measure of the stigma of mental illness. Br. J. Psychiatry 190 (2007), 248–254.
47. Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M., Miettunen, J., Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr. Bull. 36:6 (2010), 1115–1130.
48. Kovasznay, B., Fleischer, J., Tanenberg-Karant, M., Jandorf, L., Miller, A.D., Bromet, E., Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr. Bull. 23:2 (1997), 195–201.
49. Lambert, M., Conus, P., Lubman, D.I., Wade, D., Yuen, H., Moritz, S., Naber, D., McGorry, P.D., Schimmelmann, B.G., The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr. Scand. 112:2 (2005), 141–148.
50. Larsen, T.K., Melle, I., Auestad, B., Friis, S., Haahr, U., Johannessen, J.O., Opjordsmoen, S., Rund, B.R., Simonsen, E., Vaglum, P., McGlashan, T.H., Substance abuse in first-episode non-affective psychosis. Schizophr. Res. 88:1–3 (2006), 55–62.
51. Lasalvia, A., Zoppei, S., Bonetto, C., Tosato, S., Zanatta, G., Cristofalo, D., De Santi, K., Bertani, M., Bissoli, S., Lazzarotto, L., Ceccato, E., Riolo, R., Marangon, V., Cremonese, C., Boggian, I., Tansella, M., Ruggeri, M., The role of experienced and anticipated discrimination in the lives of people with first-episode psychosis. Psychiatr. Serv. 65:8 (2014), 1034–1040.
52. Leeson, V.C., Harrison, I., Ron, M.A., Barnes, T.R., Joyce, E.M., The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr. Bull. 38:4 (2012), 873–880.
53. Lehman, A.F., A quality of life interview for the chronically mentally ill. Eval. Prog. Plan. 11 (1988), 51–52.
54. Lobbana, F., Barrowclough, C., Jeffery, S., Bucci, S., Taylor, K., Mallinson, S., Fitzsimmons, M., Marshall, M., Understanding factors influencing substance use in people with recent onset psychosis: a qualitative study. Soc. Sci. Med. 70:8 (2010), 1141–1147.
55. Mauri, M.C., Volonteri, L.S., De Gaspari, I.F., Colasanti, A., Brambilla, M.A., Cerruti, L., Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemiol. Ment. Health, 2, 2006, 4.
56. McCleery, A., Addington, J., Addington, D., Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr. Res. 88:1–3 (2006), 187–191.
57. McGinty, E.E., Goldman, H.H., Pescosolido, B., Barry, C.L., Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. Soc. Sci. Med. 126 (2015), 73–85.
58. McLellan, A.T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., Argeriou, M., The fifth edition of the addiction severity index. J. Subst. Abus. Treat. 9:3 (1992), 199–213.
59. van der Meer, F.J., Velthorst, E., Investigators, G.R.a.O.o.P.G, Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol. Med. 45:9 (2015), 1977–1988.
60. Moran, P., Hodgins, S., The correlates of comorbid antisocial personality disorder in schizophrenia. Schizophr. Bull. 30:4 (2004), 791–802.
61. Mueser, K.T., Nishith, P., Tracy, J.I., DeGirolamo, J., Molinaro, M., Expectations and motives for substance use in schizophrenia. Schizophr. Bull. 21:3 (1995), 367–378.
62. Mueser, K.T., Drake, R.E., Ackerson, T.H., Alterman, A.I., Miles, K.M., Noordsy, D.L., Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. J. Abnorm. Psychol. 106 (1997), 473–477.
63. Mueser, K.T., Rosenberg, S.D., Drake, R.E., Miles, K.M., Wolford, G., Vidaver, R., Carrieri, K., Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders. J. Stud. Alcohol 60:2 (1999), 278–284.
64. Mueser, K.T., Crocker, A.G., Frisman, L.B., Drake, R.E., Covell, N.H., Essock, S.M., Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders. Schizophr. Bull. 32:4 (2006), 626–636.
65. Myles, H., Myles, N., Large, M., Cannabis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use. Aust. N. Z. J. Psychiatry 50:3 (2016), 208–219.
66. Patel, R., Wilson, R., Jackson, R., Ball, M., Shetty, H., Broadbent, M., Stewart, R., McGuire, P., Bhattacharyya, S., Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open, 6(3), 2016, e009888.
67. Power, B.D., Dragovic, M., Jablensky, A., Stefanis, N.C., Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia?. Aust. N. Z. J. Psychiatry 47:1 (2013), 51–58.
68. Rabinowitz, J., Bromet, E.J., Lavelle, J., Carlson, G., Kovasznay, B., Schwartz, J.E., Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol. Med. 28:6 (1998), 1411–1419.
69. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., Goodwin, F.K., Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 264:19 (1990), 2511–2518.
70. Reiss, S., Levitan, G.W., Szyszko, J., Emotional disturbance and mental retardation: diagnostic overshadowing. Am. J. Ment. Defic. 86:6 (1982), 567–574.
71. Rosenheck, R., Kasprow, W., Frisman, L., Liu-Mares, W., Cost-effectiveness of supported housing for homeless persons with mental illness. Arch. Gen. Psychiatry 60 (2003), 940–951.
72. Rosenheck, R.A., Leslie, D.L., Sindelar, J., Miller, E.A., Lin, H., Stroup, T.S., McEvoy, J., Davis, S.M., Keefe, R.S., Swartz, M., Perkins, D.O., Hsiao, J.K., Lieberman, J., Investigators, C.S., Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry 163:12 (2006), 2080–2089.
73. Ryff, C.D., Happiness is everything, or is it? Explorations on the meaning of psychological well-being. J. Pers. Soc. Psychol. 57:6 (1989), 1069–1081.
74. Sara, G., Burgess, P., Malhi, G.S., Whiteford, H., Hall, W., Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr. Res. 147:2–3 (2013), 216–222.
75. Sara, G.E., Burgess, P.M., Malhi, G.S., Whiteford, H.A., Hall, W.C., Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust. N. Z. J. Psychiatry 48:11 (2014), 1036–1047.
76. Secades-Villa, R., Garcia-Rodriguez, O., Jin, C.J., Wang, S., Blanco, C., Probability and predictors of the cannabis gateway effect: a national study. Int. J. Drug Policy 26:2 (2015), 135–142.
77. Seddon, J.L., Birchwood, M., Copello, A., Everard, L., Jones, P.B., Fowler, D., Amos, T., Freemantle, N., Sharma, V., Marshall, M., Singh, S.P., Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: a report from the UK national EDEN study. Schizophr. Bull. 42:3 (2016), 619–625.
78. de la Serna, E., Mayoral, M., Baeza, I., Arango, C., Andres, P., Bombin, I., Gonzalez, C., Rapado, M., Robles, O., Rodriguez-Sanchez, J.M., Zabala, A., Castro-Fornieles, J., Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J. Nerv. Ment. Dis. 198:2 (2010), 159–162.
79. Sevy, S., Robinson, D.G., Holloway, S., Alvir, J.M., Woerner, M.G., Bilder, R., Goldman, R., Lieberman, J., Kane, J., Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 104:5 (2001), 367–374.
80. Sevy, S., Robinson, D.G., Napolitano, B., Patel, R.C., Gunduz-Bruce, H., Miller, R., McCormack, J., Lorell, B.S., Kane, J., Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr. Res. 120:1–3 (2010), 101–107.
81. Silva, T.B., Balbino, C.Q., Weiber, A.F., The relationship between cannabidiol and psychosis: a review. Ann. Clin. Psychiatry 27:2 (2015), 134–141.
82. Sorbara, F., Liraud, F., Assens, F., Abalan, F., Verdoux, H., Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur. Psychiatry 18:3 (2003), 133–136.
83. Stefanis, N.C., Dragovic, M., Power, B.D., Jablensky, A., Castle, D., Morgan, V.A., The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophr. Res. 156:2–3 (2014), 211–216.
84. Stirling, J., Lewis, S., Hopkins, R., White, C., Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 75 (2005), 135–137.
85. Togay, B., Noyan, H., Tasdelen, R., Ucok, A., Clinical variables associated with suicide attempts in schizophrenia before and after the first episode. Psychiatry Res. 229:1–2 (2015), 252–256.
86. Tosato, S., Lasalvia, A., Bonetto, C., Mazzoncini, R., Cristofalo, D., De Santi, K., Bertani, M., Bissoli, S., Lazzarotto, L., Marrella, G., Lamonaca, D., Riolo, R., Gardellin, F., Urbani, A., Tansella, M., Ruggeri, M., The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J. Psychiatr. Res. 47:4 (2013), 438–444.
87. Turkington, A., Mulholland, C.C., Rushe, T.M., Anderson, R., McCaul, R., Barrett, S.L., Barr, R.S., Cooper, S.J., Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br. J. Psychiatry 195:3 (2009), 242–248.
88. Van Mastrigt, S., Addington, J., Addington, D., Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 39 (2004), 69–72.
89. Verdoux, H., Liraud, F., Gonzales, B., Assens, F., Abalan, F., van Os, J., Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatr. Scand. 100:5 (1999), 389–395.
90. Verdoux, H., Liraud, F., Gonzales, B., Assens, F., Abalan, F., van Os, J., Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatr. Scand. 103:5 (2001), 347–354.
91. Wade, D., Harrigan, S., Edwards, J., Burgess, P.M., Whelan, G., McGorry, P.D., Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis. Aust. N. Z. J. Psychiatry 39 (2005), 892–898.
92. Wade, D., Harrigan, S., Edwards, J., Burgess, P.M., Whelan, G., McGorry, P.D., Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br. J. Psychiatry 189 (2006), 229–234.
93. Wade, D., Harrigan, S., McGorry, P.D., Burgess, P.M., Whelan, G., Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J. Clin. Psychiatry 68:5 (2007), 767–774.
94. Wagner, F.A., Anthony, J.C., From first drug use to drug dependence: developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 26:4 (2002), 479–488.
95. Wallwork, R.S., Fortgang, R., Hashimoto, R., Weinberger, D.R., Dickinson, D., Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr. Res. 137:1–3 (2012), 246–250.
96. Williams, G.C., Rodin, G.C., Ryan, R.M., Grolnick, W.S., Deci, E.L., Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychol. 17:3 (1998), 269–276.
97. Wisdom, J.P., Manuel, J.I., Drake, R.E., Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatr. Serv. 62:9 (2011), 1007–1012.
98. Young, S.L., Bullock, W.A., The Mental Health Recovery Measure. 2003, University of Toledo, Toledo, Ohio.
99. Zarate, C.A. Jr., Weinstock, L., Cukor, P., Morabito, C., Leahy, L., Burns, C., Baer, L., Applicability of telemedicine for assessing patients with schizophrenia: acceptance and reliability. J. Clin. Psychiatry 58:1 (1997), 22–25.